Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash-to-Debt 0.10
DHR's Cash-to-Debt is ranked lower than
95% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. DHR: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
DHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.15 Max: 1.33
Current: 0.1
0
1.33
Equity-to-Asset 0.58
DHR's Equity-to-Asset is ranked lower than
58% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DHR: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
DHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.51 Max: 0.67
Current: 0.58
0.27
0.67
Debt-to-Equity 0.39
DHR's Debt-to-Equity is ranked lower than
53% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. DHR: 0.39 )
Ranked among companies with meaningful Debt-to-Equity only.
DHR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.13  Med: 0.36 Max: 1.6
Current: 0.39
0.13
1.6
Debt-to-EBITDA 2.35
DHR's Debt-to-EBITDA is ranked lower than
59% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. DHR: 2.35 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DHR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.79  Med: 1.44 Max: 4.21
Current: 2.35
0.79
4.21
Interest Coverage 19.44
DHR's Interest Coverage is ranked lower than
60% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. DHR: 19.44 )
Ranked among companies with meaningful Interest Coverage only.
DHR' s Interest Coverage Range Over the Past 10 Years
Min: 12.58  Med: 17.66 Max: 22.1
Current: 19.44
12.58
22.1
Piotroski F-Score: 7
Altman Z-Score: 3.52
Beneish M-Score: -2.52
WACC vs ROIC
7.86%
7.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating Margin % 16.69
DHR's Operating Margin % is ranked higher than
85% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. DHR: 16.69 )
Ranked among companies with meaningful Operating Margin % only.
DHR' s Operating Margin % Range Over the Past 10 Years
Min: 13.79  Med: 16.02 Max: 17.07
Current: 16.69
13.79
17.07
Net Margin % 13.56
DHR's Net Margin % is ranked higher than
88% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. DHR: 13.56 )
Ranked among companies with meaningful Net Margin % only.
DHR' s Net Margin % Range Over the Past 10 Years
Min: 10.3  Med: 13.95 Max: 23.26
Current: 13.56
10.3
23.26
ROE % 10.03
DHR's ROE % is ranked higher than
70% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. DHR: 10.03 )
Ranked among companies with meaningful ROE % only.
DHR' s ROE % Range Over the Past 10 Years
Min: 10.1  Med: 13.17 Max: 14.27
Current: 10.03
10.1
14.27
ROA % 5.54
DHR's ROA % is ranked higher than
75% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. DHR: 5.54 )
Ranked among companies with meaningful ROA % only.
DHR' s ROA % Range Over the Past 10 Years
Min: 5.42  Med: 7.58 Max: 8.58
Current: 5.54
5.42
8.58
ROC (Joel Greenblatt) % 80.18
DHR's ROC (Joel Greenblatt) % is ranked higher than
90% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. DHR: 80.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 59.73  Med: 80.59 Max: 118.82
Current: 80.18
59.73
118.82
3-Year Revenue Growth Rate 13.00
DHR's 3-Year Revenue Growth Rate is ranked higher than
69% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. DHR: 13.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 10.1 Max: 47.6
Current: 13
-9.7
47.6
3-Year EBITDA Growth Rate 14.90
DHR's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DHR: 14.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -21.1  Med: 14.9 Max: 51.5
Current: 14.9
-21.1
51.5
3-Year EPS without NRI Growth Rate 15.20
DHR's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DHR: 15.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: 14.7 Max: 92
Current: 15.2
-33.7
92
GuruFocus has detected 2 Warning Signs with Danaher Corp DHR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DHR's 30-Y Financials

Financials (Next Earnings Date: 2018-07-20)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income
» DHR's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades
Q1 2017

DHR Guru Trades in Q1 2017

Caxton Associates 7,300 sh (New)
Ray Dalio 16,638 sh (New)
Louis Moore Bacon 125,201 sh (+222.84%)
Robert Olstein 65,000 sh (+18.18%)
Ken Fisher 5,224 sh (+1.89%)
Chuck Akre 1,655,300 sh (unchged)
John Hussman 30,000 sh (unchged)
John Griffin 1,760,000 sh (unchged)
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Dodge & Cox 5,099,223 sh (-2.34%)
Ruane Cunniff 1,664,622 sh (-3.96%)
Murray Stahl 34,135 sh (-4.08%)
Jim Simons 1,459,300 sh (-4.13%)
Mario Gabelli 10,696 sh (-4.47%)
Daniel Loeb 3,100,000 sh (-4.62%)
First Eagle Investment 2,623,552 sh (-16.90%)
Joel Greenblatt 269,309 sh (-35.99%)
» More
Q2 2017

DHR Guru Trades in Q2 2017

Paul Tudor Jones 30,918 sh (New)
Steven Cohen 697,114 sh (New)
Louis Moore Bacon 214,900 sh (+71.64%)
Jim Simons 1,697,400 sh (+16.32%)
First Eagle Investment 2,925,603 sh (+11.51%)
Daniel Loeb 3,300,000 sh (+6.45%)
Ken Fisher 5,423 sh (+3.81%)
Dodge & Cox 5,250,773 sh (+2.97%)
Robert Olstein 65,000 sh (unchged)
Chuck Akre 1,655,300 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 10,616 sh (-0.75%)
Ruane Cunniff 1,648,054 sh (-1.00%)
Murray Stahl 33,664 sh (-1.38%)
Caxton Associates 7,100 sh (-2.74%)
John Griffin 1,487,700 sh (-15.47%)
» More
Q3 2017

DHR Guru Trades in Q3 2017

Arnold Van Den Berg 100,650 sh (New)
Wallace Weitz 209,870 sh (New)
Ray Dalio 18,745 sh (New)
Joel Greenblatt 26,710 sh (New)
MS Global Franchise Fund 116,462 sh (New)
Signature Select Canadian Fund 67,416 sh (New)
Eaton Vance Worldwide Health Sciences Fund 291,350 sh (New)
Steven Cohen 2,626,865 sh (+276.82%)
Daniel Loeb 3,300,000 sh (unchged)
Chuck Akre 1,655,300 sh (unchged)
Ruane Cunniff Sold Out
Caxton Associates Sold Out
Dodge & Cox 5,217,123 sh (-0.64%)
Mario Gabelli 10,305 sh (-2.93%)
Robert Olstein 63,000 sh (-3.08%)
Ken Fisher 5,145 sh (-5.13%)
Murray Stahl 28,908 sh (-14.13%)
Paul Tudor Jones 26,169 sh (-15.36%)
Louis Moore Bacon 178,395 sh (-16.99%)
John Griffin 1,124,700 sh (-24.40%)
First Eagle Investment 1,568,751 sh (-46.38%)
Jim Simons 96,300 sh (-94.33%)
» More
Q4 2017

DHR Guru Trades in Q4 2017

Vanguard Health Care Fund 3,798,100 sh (New)
Pioneer Investments 642,562 sh (New)
Tom Russo 1,400 sh (New)
Jim Simons 1,149,900 sh (+1094.08%)
Joel Greenblatt 127,041 sh (+375.63%)
MS Global Franchise Fund 171,229 sh (+47.03%)
Wallace Weitz 239,870 sh (+14.29%)
Ken Fisher 5,560 sh (+8.07%)
Daniel Loeb 3,310,000 sh (+0.30%)
Chuck Akre 1,655,300 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 291,350 sh (unchged)
First Eagle Investment Sold Out
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Dodge & Cox 5,192,223 sh (-0.48%)
Arnold Van Den Berg 98,955 sh (-1.68%)
Mario Gabelli 9,965 sh (-3.30%)
Robert Olstein 54,000 sh (-14.29%)
Louis Moore Bacon 136,482 sh (-23.49%)
Murray Stahl 21,488 sh (-25.67%)
John Griffin 720,000 sh (-35.98%)
Steven Cohen 281,112 sh (-89.30%)
» More
» Details

Insider Trades

Financial Reports

Latest Guru Trades with DHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-12-31 Reduce -0.48%$85.26 - $94.62 $ 101.3411%5,192,223
Vanguard Health Care Fund 2017-12-31 New Buy0.77%$85.26 - $94.62 $ 101.3411%3,798,100
Wallace Weitz 2017-12-31 Add 14.29%0.12%$85.26 - $94.62 $ 101.3411%239,870
Joel Greenblatt 2017-12-31 Add 375.63%0.13%$85.26 - $94.62 $ 101.3411%127,041
Arnold Van Den Berg 2017-12-31 Reduce -1.68%0.02%$85.26 - $94.62 $ 101.3411%98,955
Robert Olstein 2017-12-31 Reduce -14.29%0.1%$85.26 - $94.62 $ 101.3411%54,000
Mario Gabelli 2017-12-31 Reduce -3.30%$85.26 - $94.62 $ 101.3411%9,965
Ken Fisher 2017-12-31 Add 8.07%$85.26 - $94.62 $ 101.3411%5,560
First Eagle Investment 2017-12-31 Sold Out 0.3%$85.26 - $94.62 $ 101.3411%0
Dodge & Cox 2017-09-30 Reduce -0.64%$79.29 - $88.45 $ 101.3421%5,217,123
First Eagle Investment 2017-09-30 Reduce -46.38%0.27%$79.29 - $88.45 $ 101.3421%1,568,751
Wallace Weitz 2017-09-30 New Buy0.76%$79.29 - $88.45 $ 101.3421%209,870
Arnold Van Den Berg 2017-09-30 New Buy1.21%$79.29 - $88.45 $ 101.3421%100,650
Robert Olstein 2017-09-30 Reduce -3.08%0.02%$79.29 - $88.45 $ 101.3421%63,000
Joel Greenblatt 2017-09-30 New Buy0.03%$79.29 - $88.45 $ 101.3421%26,710
Mario Gabelli 2017-09-30 Reduce -2.93%$79.29 - $88.45 $ 101.3421%10,305
Ken Fisher 2017-09-30 Reduce -5.13%$79.29 - $88.45 $ 101.3421%5,145
Ruane Cunniff 2017-09-30 Sold Out 1.29%$79.29 - $88.45 $ 101.3421%0
Dodge & Cox 2017-06-30 Add 2.97%0.01%$81.7 - $86.84 $ 101.3420%5,250,773
First Eagle Investment 2017-06-30 Add 11.51%0.06%$81.7 - $86.84 $ 101.3420%2,925,603
Ruane Cunniff 2017-06-30 Reduce -1.00%0.01%$81.7 - $86.84 $ 101.3420%1,648,054
Mario Gabelli 2017-06-30 Reduce -0.75%$81.7 - $86.84 $ 101.3420%10,616
Ken Fisher 2017-06-30 Add 3.81%$81.7 - $86.84 $ 101.3420%5,423
Joel Greenblatt 2017-06-30 Sold Out 0.29%$81.7 - $86.84 $ 101.3420%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:TMO, XAMS:PHIA, NYSE:A, NYSE:IQV, TSE:6869, XSWX:LONN, NAS:IDXX, NYSE:LH, NYSE:DGX, XPAR:ERF, SZSE:300676, XTER:SRT3, XPAR:BIM, NYSE:PKI, NYSE:BIO, NYSE:QGEN, NAS:ICLR, NAS:DXCM, XTER:AFX, NAS:PRAH » details
Traded in other countries:DHER34.Brazil, DAP.Germany, DHR.Mexico, DHR.Switzerland, 0R2B.UK,
Headquarter Location:USA
Danaher Corp designs, manufactures and markets professional, medical, industrial and commercial products and services. It markets its products under the brand of Beckman Coulter, Aperio, Dexis, Chemtreat and others.

After the spin-off of Fortive in 2016, Danaher is a diversified and mostly healthcare-focused instrument and supplies manufacturer. After the spin, Danaher retains four main business segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. Each segment represents approximately 31%, 32%, 15%, and 22% of revenue, respectively.

Guru Investment Theses on Danaher Corp

Keeley Funds Comments on Danaher Corp - Oct 24, 2017

Notable activity included continuing to build our initial position in DXC Technology and initiating a new, small position in Danaher Corp. Danaher (NYSE:DHR) has an outstanding track record of operational excellence through the application of Lean Manufacturing practices and culture, as well as astute acquirers. Recently the company has spun its industrial-focused assets into a separate entity, and the new Danaher is focused on life sciences, diagnostics, environmental and dental industries. We believe this “new” Danaher has the opportunity to continue compounding its business value for many years to come.

From Wallace Weitz (Trades, Portfolio)'s Partners III Fund third-quarter 2017 shareholder commentary.

Check out Keeley Asset Management Corp latest stock trades

Daniel Loeb Comments on Danaher - Apr 27, 2016

Danaher (DHR) is a diversified multi-industrial company with an increasing exposure to life science and healthcare-oriented businesses. Operating across five different business segments and built up through over 400 acquisitions over the company’s history, the cornerstone for Danaher’s successful integration and value creation strategy has been the

Danaher Business System (DBS). Adapted from Japanese principles of kaizen, DBS has evolved into a set of processes and corporate culture revolving around continuous improvement, helping to drive organic growth and annual margin improvement across Danaher’s portfolio.

In May 2015, Danaher announced the acquisition of a filtration industry leader, Pall Corp, as well as the subsequent split of Danaher into two companies. The split, to be effectuated Q3 2016, will highlight value at both New Danaher – a collection of Danaher’s life science, medical and lower cyclicality businesses – and the spin-off, Fortive – an industrial focused “mini-Danaher”.

New Danaher, representing the large majority of post-split value, will have 60% consumables sales mix, 4% organic growth, 100bps of annual margin expansion, and>100% FCF conversion, an algorithm that will continue the Danaher tradition of compounded earnings growth. The attractive end-market mix, earnings growth, and deep bench of DBS operators will make New Danaher a premium life sciences company that should trade at the high end of its peer group.

Fortive, akin to what Danaher originally looked like two decades ago, will have greatly increased M&A optionality and the ability to deploy free cash flow into assets which have historically received less focus within the Danaher portfolio. With the same DBS roots and team of disciplined operators, Fortive will also provide a multi-year compounding opportunity.

We initiated a position following the announcements last summer which mark a transformational step in Danaher’s decade-long efforts to continuously improve its portfolio of businesses. Despite Danaher’s portfolio of businesses looking more attractive than ever, its current valuation premium to the S&P 500 is modest and remains well below its ten year historical average premium. Over the last ten years, Danaher has compounded at 2x the rate of the S&P 500. We recently added to the position after a meeting with the company reinforced our confidence not only in their operations but also in the company’s culture and importance of their values and principles in driving future success.

From Daniel Loeb (Trades, Portfolio)'s first quarter 2016 shareholder letter.

Check out Daniel Loeb latest stock trades

Top Ranked Articles about Danaher Corp

Danaher Reports First Quarter 2018 Results
April 19, 2018
Read more...
Beckman Coulter Diagnostics Announces Worldwide Commercialization of the Access Sensitive Estradiol
April 10, 2018
Read more...
Danaher Schedules First Quarter 2018 Earnings Conference Call
March 19, 2018
Read more...
MS Global Franchise Fund Starts 2 Positions in 4th Quarter Fund exits Time Warner position
March 12, 2018
The MS Global Franchise Fund (Trades, Portfolio), part of Morgan Stanley, reported its fourth-quarter portfolio last week, disclosing it established two new positions and exited another. Read more...
Danaher to Acquire Integrated DNA Technologies
March 9, 2018
Read more...
Danaher Provides Update On First Quarter 2018 Financial Performance
March 7, 2018
Read more...
Danaher Announces Quarterly Dividend
February 20, 2018
Read more...
Danaher To Present At Barclays Industrial Select Conference
February 14, 2018
Read more...
What Can We Do Now? Part II A list of ways to help us remain calm
February 4, 2018
About four months ago, I wrote an article titled “What Can We Do Now?” Since then the market continued to rise undisrupted until this week. This headline from CNBC summarized what happened – “Dow Plummets 666 points, capping worst week in two years.” I was just on CNBC’s mobile website and the first 10 headlines are all about the Friday sell-off. The CBOE Volatility Index shot up 28.5% in one day. There’s little doubt that there’s wide spread mini panic in the market. The question of “what can we do now?” is again on investors’ mind. But this time the seeking of an answer seems much more urgent and important than when I wrote the article in September last year. Read more...
Vanguard Health Care Fund Buys Danaher, CVS Health, Adds to Allergan The fund's largest buys of the 4th quarter
February 1, 2018
The Vanguard Health Care Fund (Trades, Portfolio) increased many holdings and established several other positions in the fourth quarter. The fund's nine largest trades are as follows: Read more...

Ratios

vs
industry		 vs
history
PE Ratio 28.07
DHR's PE Ratio is ranked higher than
60% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. DHR: 28.07 )
Ranked among companies with meaningful PE Ratio only.
DHR' s PE Ratio Range Over the Past 10 Years
Min: 9.61  Med: 14.69 Max: 29.41
Current: 28.07
9.61
29.41
Forward PE Ratio 23.15
DHR's Forward PE Ratio is ranked lower than
53% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DHR: 23.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 28.07
DHR's PE Ratio without NRI is ranked higher than
60% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. DHR: 28.07 )
Ranked among companies with meaningful PE Ratio without NRI only.
DHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.66  Med: 15.77 Max: 38.03
Current: 28.07
9.66
38.03
PB Ratio 2.60
DHR's PB Ratio is ranked higher than
70% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. DHR: 2.60 )
Ranked among companies with meaningful PB Ratio only.
DHR' s PB Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.84 Max: 2.74
Current: 2.6
1.19
2.74
PS Ratio 3.81
DHR's PS Ratio is ranked lower than
53% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. DHR: 3.81 )
Ranked among companies with meaningful PS Ratio only.
DHR' s PS Ratio Range Over the Past 10 Years
Min: 1.01  Med: 1.94 Max: 4.35
Current: 3.81
1.01
4.35
Price-to-Free-Cash-Flow 22.76
DHR's Price-to-Free-Cash-Flow is ranked higher than
59% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. DHR: 22.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.59  Med: 13.29 Max: 25.64
Current: 22.76
7.59
25.64
Price-to-Operating-Cash-Flow 19.12
DHR's Price-to-Operating-Cash-Flow is ranked lower than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. DHR: 19.12 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.81  Med: 11.53 Max: 21.07
Current: 19.12
6.81
21.07
EV-to-EBIT 24.86
DHR's EV-to-EBIT is ranked lower than
55% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. DHR: 24.86 )
Ranked among companies with meaningful EV-to-EBIT only.
DHR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 12.5 Max: 35.6
Current: 24.86
8
35.6
EV-to-EBITDA 17.91
DHR's EV-to-EBITDA is ranked higher than
55% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. DHR: 17.91 )
Ranked among companies with meaningful EV-to-EBITDA only.
DHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.3 Max: 26.1
Current: 17.91
6.7
26.1
EV-to-Revenue 4.27
DHR's EV-to-Revenue is ranked lower than
52% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. DHR: 4.27 )
Ranked among companies with meaningful EV-to-Revenue only.
DHR' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.1 Max: 5.4
Current: 4.27
1.2
5.4
PEG Ratio 46.83
DHR's PEG Ratio is ranked lower than
98% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. DHR: 46.83 )
Ranked among companies with meaningful PEG Ratio only.
DHR' s PEG Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.11 Max: 218.45
Current: 46.83
0.55
218.45
Shiller PE Ratio 28.93
DHR's Shiller PE Ratio is ranked higher than
77% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. DHR: 28.93 )
Ranked among companies with meaningful Shiller PE Ratio only.
DHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.2  Med: 22.71 Max: 32.9
Current: 28.93
15.2
32.9
Current Ratio 1.59
DHR's Current Ratio is ranked lower than
76% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. DHR: 1.59 )
Ranked among companies with meaningful Current Ratio only.
DHR' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.43 Max: 2.23
Current: 1.59
0.9
2.23
Quick Ratio 1.15
DHR's Quick Ratio is ranked lower than
80% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DHR: 1.15 )
Ranked among companies with meaningful Quick Ratio only.
DHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 0.98 Max: 1.82
Current: 1.15
0.56
1.82
Days Inventory 81.08
DHR's Days Inventory is ranked higher than
50% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. DHR: 81.08 )
Ranked among companies with meaningful Days Inventory only.
DHR' s Days Inventory Range Over the Past 10 Years
Min: 63.09  Med: 73.79 Max: 108.16
Current: 81.08
63.09
108.16
Days Sales Outstanding 63.43
DHR's Days Sales Outstanding is ranked lower than
53% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. DHR: 63.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
DHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.46  Med: 68.9 Max: 97.75
Current: 63.43
54.46
97.75
Days Payable 69.29
DHR's Days Payable is ranked higher than
53% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. DHR: 69.29 )
Ranked among companies with meaningful Days Payable only.
DHR' s Days Payable Range Over the Past 10 Years
Min: 59.9  Med: 69.77 Max: 110.7
Current: 69.29
59.9
110.7

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield % 0.57
DHR's Dividend Yield % is ranked lower than
67% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.81 vs. DHR: 0.57 )
Ranked among companies with meaningful Dividend Yield % only.
DHR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.15  Med: 0.26 Max: 0.84
Current: 0.57
0.15
0.84
Dividend Payout Ratio 0.16
DHR's Dividend Payout Ratio is ranked higher than
80% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. DHR: 0.16 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DHR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.03  Med: 0.04 Max: 0.22
Current: 0.16
0.03
0.22
3-Year Dividend Growth Rate 11.90
DHR's 3-Year Dividend Growth Rate is ranked higher than
61% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. DHR: 11.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DHR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13.2 Max: 78.6
Current: 11.9
0
78.6
Forward Dividend Yield % 0.63
DHR's Forward Dividend Yield % is ranked lower than
66% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. DHR: 0.63 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.30
DHR's 5-Year Yield-on-Cost % is ranked higher than
92% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. DHR: 4.30 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DHR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.13  Med: 1.96 Max: 6.34
Current: 4.3
1.13
6.34
3-Year Average Share Buyback Ratio 0.40
DHR's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. DHR: 0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7  Med: -1.5 Max: 0.4
Current: 0.4
-7
0.4

Valuation & Return

vs
industry		 vs
history
Earnings Yield (Greenblatt) % 4.02
DHR's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. DHR: 4.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 8 Max: 12.5
Current: 4.02
2.8
12.5
Forward Rate of Return (Yacktman) % 3.80
DHR's Forward Rate of Return (Yacktman) % is ranked lower than
69% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. DHR: 3.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.1  Med: 18.1 Max: 27.6
Current: 3.8
2.1
27.6

More Statistics

Revenue (TTM) (Mil) $18,819.40
EPS (TTM) $ 3.61
Beta1.01
Volatility13.92%
52-Week Range $78.97 - 104.82
Shares Outstanding (Mil)698.57

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 19,459 20,386 21,199
EBIT (Mil $) 3,416 3,744 3,943
EBITDA (Mil $) 4,754 5,096 5,194
EPS ($) 4.38 4.73 4.95
EPS without NRI ($) 4.38 4.73 4.95
EPS Growth Rate
(Future 3Y To 5Y Estimate)		 10.89%
Dividends per Share ($) 0.64 0.69 0.79

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

» More Articles for DHR

Headlines

Articles On GuruFocus.com
Danaher Reports First Quarter 2018 Results Apr 19 2018 
Beckman Coulter Diagnostics Announces Worldwide Commercialization of the Access Sensitive Estradiol Apr 10 2018 
Danaher Schedules First Quarter 2018 Earnings Conference Call Mar 19 2018 
MS Global Franchise Fund Starts 2 Positions in 4th Quarter Mar 12 2018 
Danaher to Acquire Integrated DNA Technologies Mar 09 2018 
Danaher Provides Update On First Quarter 2018 Financial Performance Mar 07 2018 
Danaher Announces Quarterly Dividend Feb 20 2018 
Danaher To Present At Barclays Industrial Select Conference Feb 14 2018 
What Can We Do Now? Part II Feb 04 2018 
Vanguard Health Care Fund Buys Danaher, CVS Health, Adds to Allergan Feb 01 2018 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}